ADE is a chemotherapy regimen most often used as an induction or consolidation regimen in acute myelogenous leukemia, especially in poor-risk patients or those refractory to the standard first-line induction with standard "7+3" regimen or who are relapsed after the standard chemotherapy.
ADE regimen consists of three drugs: Ara-C (cytarabine) - an antimetabolite; Daunorubicin - an anthracycline antibiotic that is able to intercalate DNA and thus disrupt the cell division cycle, preventing mitosis; Etoposide - a topoisomerase inhibitor.
Dosing regimen Drug Dose Mode Days Ara-C (cytarabine) 200 mg/m2 IV push every 12 hours in 2 divided doses (100 mg/m2 each) Days 1-10 Daunorubicin 50 mg/m2 IV slow push Days 1, 3 and 5 Etoposide 100 mg/m2 IV infusion over 1 hour Days 1-5
References